Over half of adults are predicted to be overweight by 2050. Here's why weight-loss drugs aren't a cure
Over half of all adults — and a third of children and young adults — around the world are expected to be overweight or obese ...
South African watchdog probes Novo Nordisk and Sanofi over insulin
South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...
News242h
SA watchdog to probe global giants over insulin pens
Novo Nordisk and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices ...
Weight loss jab use rising among people with eating disorders, experts warn as NHS chief calls for crackdown
Online pharmacies and private providers have been urged to “act responsibly” and ensure that the drugs are only prescribed to ...
greenqueen5h
‘Deeply Problematic’: Nutritionists Slam Ozempic Maker’s Efforts to Revise Ultra-Processed Food Classification
Over 90 nutritionists have hit back at Ozempic maker Novo Nordisk's project to update the Nova classification for ...
Pfizer Remains A Good Pick For Dividend Investors
Pfizer's Q4/24 results showed significant improvements, with total revenue up 21.9% YoY and adjusted diluted EPS increasing ...
pharmaphorum8h
Lilly uses Oscars ad to warn about 'untested' GLP-1s
It's the second year in a row that Lilly has used the Oscars as a platform to drive home a message about GLP-1-based obesity ...
Stifel Nicolaus Downgrades Novo Nordisk A/S (NYSE:NVO) to Hold
Stifel Nicolaus cut shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a buy rating to a hold rating in a report issued ...
Santa Rosa Press Democrat14h
California made a big bet on producing its own insulin. There’s no ‘date certain’ for delivery
California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.
Hosted on MSN17h
Novo Nordisk and AI-driven Gensaic enter into $354m cardiometabolic deal
Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...
AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
Drugmaker AbbVie has agreed to license a weight-loss drug currently in development from Gubra for up to about $2.2 billion, marking its entry into the obesity treatment market.